Drug Insights

Synapse Simplified: How to Find Lamotrigine Information

11 February 2024
2 min read

Lamotrigine, a pharmacological agent granted approval by the United States Food and Drug Administration (FDA) on the 27th of December, 1994, is a preeminent anticonvulsant compound forged by the pharmaceutical giant GlaxoSmithKline. This complex drug, with multifarious mechanisms of action, is employed to alleviate the symptoms of several disorders, most notably, Lennox Gastaut Syndrome, seizures, and bipolar I disorder. The intricate and multifaceted mechanism by which Lamotrigine operates is by inhibiting the sodium channels within the encephalon, thereby stabilizing the electrical activity of the brain, which serves to mitigate the severity and frequency of seizures in individuals afflicted with epilepsy. Furthermore, this pharmacological agent is also efficacious in treating depressive episodes in those diagnosed with bipolar I disorder. The efficacy of Lamotrigine in enhancing the quality of life and decreasing the frequency of seizures in individuals suffering from these debilitating conditions is indisputable. Click on the image below to begin the exploration journey of Lamotrigine through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EMA Approves Review of Tisotumab Vedotin for Advanced Cervical Cancer Therapy
Latest Hotspot
3 min read
EMA Approves Review of Tisotumab Vedotin for Advanced Cervical Cancer Therapy
11 February 2024
European Medicines Agency Approves Review of Tisotumab Vedotin Filing for Relapsed or Spreading Cervical Cancer Therapy.
Read →
A Complete Guide to Searching Magnesium citrate on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Magnesium citrate on Synapse
11 February 2024
Magnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio.
Read →
Ascendis Pharma Launches YORVIPATH® for Adult Hypoparathyroidism in Germany and Austria
Latest Hotspot
3 min read
Ascendis Pharma Launches YORVIPATH® for Adult Hypoparathyroidism in Germany and Austria
11 February 2024
Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.
Read →
Using Synapse for Your Cefdinir Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Cefdinir Research: An Easy Guide
11 February 2024
Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.